课题基金 / 基金详情

Chemokine Receptor CCR7 In Tissue-Specific T Cell Imprinting and Autoimmunity

Chemokine Receptor CCR7 In Tissue-Specific T Cell Imprinting and Autoimmunity
组织特异性 T 细胞印记和自身免疫中的趋化因子受体 CCR7
批准号:
8190270
负责人:
James J. Campbell
金额:
$22.69万
依托单位国家:
美国
项目类别:
财政年份:
2011
资助国家:
美国
项目状态:
已结题
起止时间:
2011-06-01 至 2013-05-31

项目摘要

项目成果

James J. Campbell的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Chemokine receptor CCR7 is a key regulator of both the initiation and anamnestic phases of T cell mediated immune responses. By controlling dendritic cell (DC) and T cell movements throughout the body, CCR7 can influence the balance of T cell responses towards either immunity or tolerance. Much of our knowledge relevant to the function of this receptor comes from studies of mice genetically deficient in CCR7 itself or its ligands. CCR7-deficiency results in dramatic effects throughout the immune system. Abnormalities include a global paucity of T cells; absence of naive T cells from lymph nodes; absence of various dendritic cell (DC) subsets from lymphoid organs and an increased occurrence of autoimmune symptoms. Importantly, CCR7- deficiency results in profound morphological abnormalities of the secondary lymphoid organs. Our preliminary data demonstrate that many of the abnormalities observed in these mice are most likely secondary effects of the abnormal lymph node architecture. Thus, many effects previously attributed directly to CCR7 function are in reality caused by a paucity of lymphoid microenvironments able to support normal immune function. We believe that this new, paradigm-shifting information requires us to take a "back-to-the-drawing-board" approach to more fully understand the various roles played by CCR7 in the development of immune responses within mature animals. We propose experiments that will ask: 1) How can CCR7-/- cells participate normally in tissue- specific immune responses when their precursors are exceedingly rare in the sites believed to generate tissue- specific responses? 2) Is CCR7 truly required to influence the balance between immunity and tolerance by regulating the generation of Treg cells? Our recent findings will allow us to explore CCR7 as a potential target for clinical intervention in various human autoimmune diseases, tumor immunogenicity and graft rejection. PUBLIC HEALTH RELEVANCE: CCR7 is a receptor expressed by various cells in the immune system, and it is tough to allow these cells to interact with one another to generate an immune response. This receptor has been well studied, and mice lacking this receptor have many abnormalities in their ability to mount normal immune responses. However, we have recently discovered that many of the abnormalities associated with this receptor are actually the result of malformed lymph nodes, where immune cells interact, rather than direct results of the missing receptor. This new finding requires us to re-evaluate the role played by this receptor in immune responses, which we hope to explore if this project is funded. If the conclusions from our initial findings prove correct, drugs targeting CCR7 may be useful for treating diseased that involve an over-active immune system.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Influence of Chemokine Receptors on T Cell Cytokine Profiles in Skin
  • 批准号:
    8225940
  • 项目类别:
  • 资助金额:
    $20.55万
  • 财政年份:
    2012
  • 负责人:
    James J. Campbell
  • 依托单位:
Chemokine Receptor CCR7 In Tissue-Specific T Cell Imprinting and Autoimmunity
  • 批准号:
    8272537
  • 项目类别:
  • 资助金额:
    $20.32万
  • 财政年份:
    2011
  • 负责人:
    James J. Campbell
  • 依托单位:
Loading Skin-Derived Antigen on Dendritic Cells in Vivo for T Responses in Vitro
  • 批准号:
    7707028
  • 项目类别:
  • 资助金额:
    $7.88万
  • 财政年份:
    2009
  • 负责人:
    James J. Campbell
  • 依托单位:
Loading Skin-Derived Antigen on Dendritic Cells in Vivo for T Responses in Vitro
  • 批准号:
    7860362
  • 项目类别:
  • 资助金额:
    $7.87万
  • 财政年份:
    2009
  • 负责人:
    James J. Campbell
  • 依托单位:
国内基金
海外基金
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
  • 批准号:
    JCZRQN202500010
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
  • 依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
  • 批准号:
    2025JJ70209
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
    雷芬芳
  • 依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
  • 批准号:
    --
  • 项目类别:
    面上项目
  • 资助金额:
    --
  • 批准年份:
    2024
  • 负责人:
    万荣
  • 依托单位: